analyzed bone marrow aspirates from 208 PCa patients with local disease and compared different DTC detection methods, including antibody-based enrichment with epithelial (e.g., EpCAM) and prostate-specific (e.g. NKX3.1, AR, PSA) markers and found that epithelial markers are not applicable due to unspecific binding (249). The gene discussed is EPCAM; the disease is posterior cortical atrophy.